Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

emtricitabine-rilpivirine-tenofovir disoproxil fumarate

emtricitabine-rilpivirine-tenofovir disoproxil fumarate
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Complera TABLET, ORAL 200 mg-25 mg-300 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

emtricitabine-rilpivirine-tenofovir disoproxil fumarate (Complera)                                                                                                

  • 200 mg-25 mg-300 mg tablet oral

emtricitabine (Emtriva) AND rilpivirine (Edurant) AND tenofovir disoproxil fumarate (Viread)

  • ONE 200 mg emtricitabine capsule oral PLUS ONE 25 mg rilpivirine tablet oral PLUS ONE 300 mg tenofovir disoproxil fumarate tablet oral

Dispense individual components separately

Reviewed: September 27, 2011

 

Last updated: Dec. 20, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved